Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries

Sarepta Therapeutics (SRPT) reported strong Q2 2025 results, with adjusted EPS of $2.02 and total revenue of $611.1 million, both significantly beating consensus estimates, primarily driven by a 132% year-over-year surge in Elevidys sales and a $63.5 million milestone payment from Roche. Crucially, the company announced the resumption of Elevidys shipments following FDA clearance for ambulatory patients, mitigating concerns from recent patient deaths and leading to a more than 10% stock surge. SRPT also initiated a strategic restructuring, including a 36% workforce reduction and pipeline reprioritization, aiming for $400 million in annual savings from 2026, signaling a focus on operational efficiency and core assets.

Analysis

Sarepta Therapeutics (SRPT) delivered a significant second-quarter 2025 earnings beat, with an adjusted EPS of $2.02 and revenue of $611.1 million, surpassing consensus estimates of $1.11 and $529.5 million, respectively. The outperformance was primarily fueled by a 132% year-over-year surge in sales of its gene therapy, Elevidys, which reached $281.9 million, and a $63.5 million milestone payment from its partner, Roche. This strong growth in Elevidys contrasts with a 3% decline in the company's older PMO therapies, underscoring a strategic pivot toward the newer gene therapy asset. Critically, the company announced the resumption of Elevidys shipments following FDA clearance for ambulatory patients, a major de-risking event that prompted a more than 10% after-hours stock increase. This positive development follows a period of intense pressure due to patient deaths linked to its AAVrh74 vector, which led to a suspension of full-year Elevidys guidance. In response to these challenges, SRPT has initiated a substantial restructuring plan aiming for $400 million in annual savings by 2026, involving a 36% workforce reduction and a pipeline reprioritization away from its LGMD programs toward siRNA assets acquired from Arrowhead. While the stock has plunged 87% year-to-date, the combination of a strong quarter, positive regulatory news, and a clear strategic restructuring provides a new, albeit high-risk, narrative for the company.

Key Decisions for Investors

• Given the FDA's clearance for Elevidys in ambulatory patients and the strong earnings beat, investors should evaluate SRPT as a high-risk, high-reward turnaround story, balancing the recent stock rally against the severe 87% year-to-date decline.
• Monitor the sales trajectory of Elevidys closely, as its successful ramp-up following the resumption of shipments is now the single most critical value driver for the company, especially with formal guidance suspended.
• The strategic pivot to siRNA programs and the aggressive $400 million cost-saving plan introduce significant execution risk; upcoming data from the new FSHD and DM1 programs before year-end will be key catalysts for validating this new direction.
• Remain cautious of the lingering safety overhang from the AAVrh74 vector in non-ambulatory patients, as any further adverse events or regulatory setbacks could swiftly reverse the current positive sentiment.